Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"

   Hotel Registration
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Wissenschaftliches Programm
   Scientific program
   Poster Presentation
Begleitende Veranstaltungen
   Accompanying program
   Working sessions
   Social program
Allgemeine Informationen
   General Information
   Index of Authors
   Commercial exhibitors

DOG Homepage


Safety and Efficacy of Latanoprost in Pediatric Glaucoma

Autrata R., Řehurek J., Vančurova J.
Department of Ophthalmology, Masaryk University Hospital, Brno/CZ

Purpose: Latanoprost is a prostaglandin F2 analogue that substantially reduces intraocular pressure (IOP) via enhancement of uveoscleral outflow and IOP-lowering effect has been shown to be additive in combined therapy with other ocular hypotensive agents. The purpose of this study was to examine the effectiveness and safety profile of latanoprost therapy in children with glaucoma.
Method: This study was designed as a prospective study of all patients who were administered latanoprost at our clinic between January 1998 and December 2001. Sixty-four eyes of 51 pediatric patients with a variety of glaucoma diagnoses were included in the study, and were observed with an average of 21 months (range 13 to 37 months). The mean age of the patients was 7.8 years (range, 5 months to 16 years). The baseline IOP was compared with the IOP during the whole time of latanoprost therapy for each patient, visual acuity and side effects were noted at each follow-up examination. Responders were defined as those who had at least a 10% IOP reduction on latanoprost, whereas nonresponders showed less than a 10% IOP reduction on latanoprost.
Results: The mean pretreatment IOP was 24.9 ± 4.8 mm Hg, whereas the posttreatment IOP was 22.6 ± 7.5 mm Hg. The mean IOP reduction for this group after the addition of latanoprost was 9.2% (2.3 mm Hg). Twenty-one patients

Zurück | Back